Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRLD | US
0.03
1.57%
Healthcare
Biotechnology
30/06/2024
16/10/2024
1.94
1.92
2.01
1.88
Prelude Therapeutics Incorporated a clinical-stage biopharmaceutical company focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811 which is in Phase 1 clinical trials in solid tumors including glioblastoma. The company is also developing PRT1419 a myeloid cell leukemia-1 inhibitor which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527 a cyclin-dependent kinase 4/6 inhibitor which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645 a cyclin-dependent kinase 4/6 inhibitor which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879 a SMARCA2 selective protein degrader which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington Delaware.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
43.7%1 month
60.5%3 months
149.7%6 months
131.1%-
-
0.59
0.10
0.08
-0.54
-
-
-140.78M
105.93M
105.93M
-
-
-
-
-58.45
5.27
14.35
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.26
Range1M
1.02
Range3M
4.98
Rel. volume
2.12
Price X volume
1.36M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
QSI | QSI | Biotechnology | 0.8164 | 116.22M | -3.04% | n/a | 0.71% |
ELEDON PHARMACEUTICALS INC | ELDN | Biotechnology | 2.93 | 116.19M | -0.68% | 5.96 | -7.70% |
Assembly Biosciences Inc | ASMB | Biotechnology | 17.59 | 111.62M | -5.02% | n/a | 5.03% |
CIBUS GLOBAL LTD. | CBUS | Biotechnology | 3.7 | 109.12M | 5.11% | n/a | 81.33% |
Adagene Inc. | ADAG | Biotechnology | 2.39 | 107.80M | 1.70% | n/a | 36.49% |
GENELUX CORP | GNLX | Biotechnology | 3.09 | 106.71M | -3.13% | n/a | 5.86% |
Genenta Science S.p.A | GNTA | Biotechnology | 5.85 | 106.57M | 0.86% | n/a | 0.00% |
I-MAB | IMAB | Biotechnology | 1.35 | 106.38M | 0.75% | n/a | 1.67% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.59 | 104.09M | 6.00% | n/a | 1.45% |
INmune Bio Inc | INMB | Biotechnology | 5.21 | 103.32M | 7.87% | n/a | 14.65% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.49 | 93.31M | 1.12% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.34 | 89.79M | -0.14% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.5 | 19.04M | 4.17% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.02 | 18.42M | 2.01% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6542 | 9.49M | -5.19% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2051 | 3.68M | -6.82% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.09 | 2.84M | -0.91% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -0.99% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.42 | 0 | 2.63% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.21 | 0 | 3.19% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.54 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 0.59 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 149.71 | 72.92 | Riskier |
Debt to Equity | 0.10 | -1.24 | Expensive |
Debt to Assets | 0.08 | 0.25 | Cheaper |
Market Cap | 105.93M | 3.78B | Emerging |